HLB Pep
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
HLB Pep develops peptide-based drug candidates, short chains of amino acids engineered to treat diseases, targeting conditions such as cancer, type-two diabetes, metabolic obesity, bacterial infections, viral infections, and ulcerative colitis.
Its pipeline is aimed at addressing unmet patient needs where existing treatments fall short, and its drug candidates are developed in collaboration with domestic and international specialists. Listed on KOSDAQ, Korea's tech and small-cap board, the company's business is built entirely around an early-stage drug pipeline, with multiple candidates holding patents across several major markets.
Summary is AI-generated and may contain errors · figures from DART filings
HLB Pep in five facts
What does HLB Pep do?
HLB Pep develops peptide-based drug candidates, short chains of amino acids engineered to treat diseases, targeting conditions such as cancer, type-two diabetes, metabolic obesity, bacterial infections, viral infections, and ulcerative colitis.
Where is HLB Pep listed and in which sector?
HLB Pep (Korean name: HLB펩) trades under KRX code 196300 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is HLB Pep?
Its market capitalisation was US$30.7M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were HLB Pep's latest annual revenue and operating profit?
For fiscal year 2025, HLB Pep reported revenue of US$3.7M, an operating loss of US$5.5M and a net loss of US$484.9K, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was down 20.3% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] Investor relations (IR) meetingOct 12
- Investor relations (IR) meetingOct 12
- Material event report (decision to redeem own convertible bonds early)Capital raise · Sep 9
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
HLB Pep reported separate results for FY2025: revenue of US$3.39M (−20.3% year on year), an operating loss of US$5M and a net loss of US$439K.
Earnings · Mar 10 - Supply contract signedSupply contract · Jan 2